文献速递前列腺癌

BRCA2/SPOP共突变预测转移性去势抵抗性前列腺癌对聚腺苷二磷酸核糖聚合酶抑制剂的卓越敏感性

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-12-09

这项多中心回顾性研究纳入131例BRCA2突变且接受PARP抑制剂治疗的转移性去势抵抗性前列腺癌患者,其中14例合并SPOP突变。合并SPOP突变者PSA缓解率86%(12/14) vs 60%(70/117)(p=0.06),多变量分析显示PSA-PFS、临床/影像学PFS和OS均更长。

要点

  • BRCA2/SPOP共突变者PSA缓解率86%(12/14) vs 60%(70/117),p=0.06。
  • 多变量分析示共突变者PSA-PFS HR 0.16、临床/影像学PFS HR 0.28、OS HR 0.19。
  • 未接受PARP抑制剂队列中两组OS无差异(HR 0.97,p=0.94)。

核心结论

  • 在这项回顾性分析中,PARP抑制剂在BRCA2mut/SPOPmut患者中似乎比BRCA2mut/SPOPwt的mCRPC患者更有效。
  • 作者认为这可能与共突变疾病中同源重组修复缺陷增加有关。

研究设计与样本

  • 多中心回顾性研究,涉及13个中心。
  • 识别131例接受PARP抑制剂治疗的BRCA2突变mCRPC患者,其中14例同时携带SPOP突变。
  • 主要疗效终点为PSA缓解率(PSA下降≥50%),次要终点为生化PFS(PSA-PFS)、临床/影像学PFS和OS。

主要发现

  • PSA缓解见于BRCA2mut/SPOPwt患者的60%(70/117)和BRCA2mut/SPOPmut患者的86%(12/14)(p=0.06)。
  • PARP抑制剂治疗中位时间在BRCA2mut/SPOPmut组为24.0个月(95%CI 19.2个月至未达到) vs 仅BRCA2突变组8.0个月(95%CI 6.1-10.9个月)(p=0.05)。
  • 未调整分析中,BRCA2mut/SPOPmut患者PSA-PFS更长(HR 0.33,95%CI 0.15-0.72,p=0.005),临床/影像学PFS更长(HR 0.4,95%CI 0.18-0.86,p=0.02),OS数值上更长(HR 0.4,95%CI 0.15-1.12,p=0.08)。
  • 多变量分析中,BRCA2mut/SPOPmut患者PSA-PFS更长(HR 0.16,95%CI 0.05-0.47,校正p=0.001),临床/影像学PFS更长(HR 0.28,95%CI 0.1-0.81,校正p=0.019),OS更长(HR 0.19,95%CI 0.05-0.69,校正p=0.012)。
  • 在未接受PARP抑制剂治疗的独立队列中,BRCA2mut/SPOPmut与BRCA2mut/SPOPwt患者的OS无差异(HR 0.97,95%CI 0.40-2.4,p=0.94)。

关键数值与推荐

  • 基因组特征分析中,预测同源重组修复缺陷的COSMIC SBS3评分在BRCA2mut/SPOPmut中高于BRCA2mut/SPOPwt(p=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这是一项回顾性研究,需要额外的前瞻性验证队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: BRCA2 mutations in metastatic castration-resistant prostate cancer (mCRPC) confer sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. However, additional factors predicting PARP inhibitor efficacy in mCRPC are needed. Preclinical studies support a relationship between speckle-type POZ protein (SPOP) inactivation and PARP inhibitor sensitivity. We hypothesized that SPOP mutations may predict enhanced PARP inhibitor response in BRCA2-altered mCRPC. METHODS: We conducted a multicenter retrospective study involving 13 sites. We identified 131 patients with BRCA2-altered mCRPC treated with PARP inhibitors, 14 of which also carried concurrent SPOP mutations. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate (≥50% PSA decline). The secondary endpoints were biochemical progression-free survival (PSA-PFS), clinical/radiographic progression-free survival (PFS), and overall survival (OS). These were compared by multivariable Cox proportional hazard models adjusting for age, tumor stage, baseline PSA level, Gleason sum, prior therapies, BRCA2 alteration types, and co-occurring mutations. KEY FINDINGS AND LIMITATIONS: Baseline characteristics were similar between groups. PSA responses were observed in 60% (70/117) of patients with BRCA2mut/SPOPwt disease and in 86% (12/14) of patients with BRCA2mut/SPOPmut disease (p = 0.06). The median time on PARP inhibitor treatment was 24.0 mo (95% confidence interval [CI] 19.2 mo to not reached) in this group versus 8.0 mo (95% CI 6.1-10.9 mo) in patients with BRCA2 mutation alone (p = 0.05). In an unadjusted analysis, patients with BRCA2mut/SPOPmut disease experienced longer PSA-PFS (hazard ratio [HR] 0.33 [95% CI 0.15-0.72], p = 0.005) and clinical/radiographic PFS (HR 0.4 [95% CI 0.18-0.86], p = 0.02), and numerically longer OS (HR 0.4 [95% CI 0.15-1.12], p = 0.08). In a multivariable analysis including histology, Gleason sum, prior taxane, prior androgen receptor pathway inhibitor, stage, PSA, BRCA2 alteration characteristics, and other co-mutations, patients with BRCA2mut/SPOPmut disease experienced longer PSA-PFS (HR 0.16 [95% CI 0.05-0.47], adjusted p = 0.001), clinical/radiographic PFS (HR 0.28 [95% CI 0.1-0.81], adjusted p = 0.019), and OS (HR 0.19 [95% CI 0.05-0.69], adjusted p = 0.012). In a separate cohort of patients not treated with a PARP inhibitor, there was no difference in OS between patients with BRCA2mut/SPOPmut versus BRCA2mut/SPOPwt disease (HR 0.97 [95% CI 0.40-2.4], p = 0.94). In a genomic signature analysis, Catalog of Somatic Mutations in Cancer (COSMIC) SBS3 scores predictive of homologous recombination repair (HRR) defects were higher for BRCA2mut/SPOPmut than for BRCA2mut/SPOPwt disease (p = 0.04). This was a retrospective study, and additional prospective validation cohorts are needed. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this retrospective analysis, PARP inhibitors appeared more effective in patients with BRCA2mut/SPOPmut than in patients with BRCA2mut/SPOPwt mCRPC. This may be related to an increase in HRR defects in coaltered disease. PATIENT SUMMARY: In this study, we demonstrate that co-alteration of both BRCA2 and SPOP predicts superior clinical outcomes to treatment with poly (ADP-ribose) polymerase (PARP) inhibitors than BRCA2 alteration without SPOP mutation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Orme JJ, Taza F, De Sarkar N, et al. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Eur Urol Oncol. 2023. PMID: 38072760. doi:10.1016/j.euo.2023.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。